Sosei and Vectura Announce Start of Phase II Efficacy Study of QVA149

Sosei and Vectura Announce Start of Phase II Efficacy Study of QVA149 Tokyo, Japan and Chippenham, UK - 13 December 2007: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565) and Vectura Group plc (“Vectura”; LSE: VEC) announce the start, by Novartis, of a Phase II efficacy study of QVA149 for the treatment of chronic obstructive pulmonary disease (COPD) QVA149 is a combination of NVA237, a once-daily long-acting muscarinic antagonist (LAMA) and indacaterol, a once-daily long-acting beta-2 agonist (LABA). This second Phase II study is a randomised, double-blind, placebo-controlled, multi-centre trial to determine the effect of QVA149 on lung function in patients with moderate to severe COPD. - Ends - Enquiries: Sosei Group Corporation Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan Hiroki MAEKAWA, Representative Executive Officer, E-mail: [email protected] Tel: +81 3 5210 3399 Fax: +81 3 5210 3291 Sosei R&D Ltd. Chesterford Research Park, Saffron Walden, CB10 1XL England John DAFFURN, EVP Corporate Development, E-mail: [email protected] Tel: +44 1799 532 350 Fax: +44 1799 532 351

The release as fetched from its publisher. nxera.life ↗